Published in Rheumatol Int on September 27, 2011
Effects of physical therapy for the management of patients with ankylosing spondylitis in the biological era. Clin Rheumatol (2014) 0.84
The effectiveness of balneotherapy in chronic neck pain. Clin Rheumatol (2016) 0.84
Predictors of functional deterioration in Chinese patients with psoriatic arthritis: a longitudinal study. BMC Musculoskelet Disord (2014) 0.78
[German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 8.3 Nonpharmaceutical therapeutic measures]. Z Rheumatol (2014) 0.78
Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab. BMC Musculoskelet Disord (2015) 0.77
Concurrent Intervention With Exercises and Stabilized Tumor Necrosis Factor Inhibitor Therapy Reduced the Disease Activity in Patients With Ankylosing Spondylitis: A Meta-Analysis. Medicine (Baltimore) (2015) 0.76
The role of land and aquatic exercise in ankylosing spondylitis: a systematic review. Rheumatol Int (2017) 0.75
Effect of a 21-day balneotherapy program on blood cell counts, ponogen levels, and blood biochemical indexes in servicemen in sub-health condition. J Phys Ther Sci (2017) 0.75
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis (2009) 8.37
Ankylosing spondylitis. Lancet (2007) 6.58
ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis (2005) 4.31
Combined spa-exercise therapy is effective in patients with ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum (2001) 1.86
Hydrotherapy, balneotherapy, and spa treatment in pain management. Rheumatol Int (2004) 1.67
A brief history of spa therapy. Ann Rheum Dis (2002) 1.67
Physiotherapy interventions for ankylosing spondylitis. Cochrane Database Syst Rev (2008) 1.61
Prophylactic hydrotherapy. Rheumatology (Oxford) (2001) 1.51
Improvement of the clinical outcome in Ankylosing spondylitis by balneotherapy. Joint Bone Spine (2005) 1.39
Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum (1996) 1.35
The Cochrane review of physiotherapy interventions for ankylosing spondylitis. J Rheumatol (2005) 1.18
Combination treatment with etanercept and an intensive spa rehabilitation program in active ankylosing spondylitis. Int J Immunopathol Pharmacol (2010) 0.99
Efficacy of methotrexate in the treatment of ankylosing spondylitis: a three-year open study. Clin Rheumatol (2000) 0.97
The effect of balneotherapy on patients with ankylosing spondylitis. Scand J Rheumatol (2006) 0.88
Anti-inflammatory effect of mud-bath applications on adjuvant arthritis in rats. Clin Exp Rheumatol (2005) 0.88
Hypothalamic-pituitary-adrenal axis dysregulation in healthy subjects undergoing mud-bath applications. Arthritis Rheum (1995) 0.87
Immediate and delayed effects of treatment at the Dead Sea in patients with psoriatic arthritis. Rheumatol Int (2000) 0.85
Spa therapy for ankylosing spondylltis at the Dead Sea. Isr Med Assoc J (2005) 0.82
The efficacy of Brazilian black mud treatment in chronic experimental arthritis. Rheumatol Int (2007) 0.80
The response on glucoregulatory hormones of in vivo whole body hyperthermia. Int J Hyperthermia (1997) 0.80
Editorial review: how early should ankylosing spondylitis be treated with a tumor necrosis factor-blocker? Curr Opin Rheumatol (2010) 0.79
Physical therapy in anti-TNF treated patients with ankylosing spondylitis. Rheumatology (Oxford) (2008) 0.79
[Physical therapy and balneotherapy of arthritis]. Ther Umsch (1991) 0.76
[Stress hormones liberated by fangotherapy. ACTH and beta-endorphin levels under heat stress]. Fortschr Med (1990) 0.75
Mud-bath treatment in spondylitis associated with inflammatory bowel disease--a pilot randomised clinical trial. Joint Bone Spine (2007) 0.75
Identification of a central role for complement in osteoarthritis. Nat Med (2011) 3.11
Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) (2002) 2.86
Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis (2010) 2.71
Rehabilitation treatment in patients with ankylosing spondylitis stabilized with tumor necrosis factor inhibitor therapy: a randomized controlled trial. J Rheumatol (2011) 2.45
Autophagy in human health and disease. N Engl J Med (2013) 2.04
Gout: why is this curable disease so seldom cured? Ann Rheum Dis (2012) 1.84
Autoantibodies to proteinase 3 and myeloperoxidase in systemic sclerosis. J Rheumatol (2002) 1.49
Effect of bosentan on plasma markers of endothelial cell activity in patients with secondary pulmonary hypertension related to connective tissue diseases. J Rheumatol (2009) 1.47
The kaleidoscope of glucorticoid effects on immune system. Autoimmun Rev (2011) 1.47
Serum amyloid-A in Behçet's disease. Clin Rheumatol (2014) 1.47
Autoantibodies in polymyositis and dermatomyositis. Curr Rheumatol Rep (2013) 1.25
The Pediatric Rheumatology European Society/American College of Rheumatology/European League against Rheumatism provisional classification criteria for juvenile systemic sclerosis. Arthritis Rheum (2007) 1.23
"To be or not to be," ten years after: evidence for mixed connective tissue disease as a distinct entity. Semin Arthritis Rheum (2011) 1.15
Resistant Behçet disease responsive to anakinra. Ann Intern Med (2008) 1.15
OARSI/OMERACT initiative to define states of severity and indication for joint replacement in hip and knee osteoarthritis. An OMERACT 10 Special Interest Group. J Rheumatol (2011) 1.14
Erosive osteoarthritis. Best Pract Res Clin Rheumatol (2004) 1.10
Overlap connective tissue disease syndromes. Autoimmun Rev (2012) 1.05
Acute liver failure with renal impairment related to the abuse of senna anthraquinone glycosides. Ann Pharmacother (2005) 1.04
Pregnancy, cytokines, and disease activity in systemic lupus erythematosus. Arthritis Rheum (2004) 1.04
Adult-onset Still's disease with myocarditis successfully treated with the interleukin-1 receptor antagonist anakinra. Joint Bone Spine (2010) 1.02
Anti-dsDNA antibody isotypes in systemic lupus erythematosus: IgA in addition to IgG anti-dsDNA help to identify glomerulonephritis and active disease. PLoS One (2013) 1.01
Gout as autoinflammatory disease: new mechanisms for more appropriated treatment targets. Autoimmun Rev (2012) 1.00
Antifibroblast antibodies in systemic sclerosis induce fibroblasts to produce profibrotic chemokines, with partial exploitation of toll-like receptor 4. Arthritis Rheum (2008) 1.00
Blau syndrome, clinical and genetic aspects. Autoimmun Rev (2012) 0.99
Inflammatory osteoarthritis of the hand. Best Pract Res Clin Rheumatol (2010) 0.99
The potential role of bone scintigraphy in the detection of deep muscular fascia involvement and calcinosis cutis in anti-synthetase syndrome. Int J Rheum Dis (2013) 0.98
Disease activity patterns in a monocentric cohort of SLE patients: a seven-year follow-up study. Clin Exp Rheumatol (2012) 0.98
Dermatomyositis and malignancy of the pharynx in Caucasian patients: report of two observations. Rheumatol Int (2003) 0.97
International position paper on febuxostat. Clin Rheumatol (2010) 0.95
Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients. Clin Rheumatol (2014) 0.94
Clinical and genetic aspects of Blau syndrome: a 25-year follow-up of one family and a literature review. Autoimmun Rev (2008) 0.94
Long-term safety of anti-TNF-α in PsA patients with concomitant HCV infection: a retrospective observational multicenter study on 15 patients. Clin Rheumatol (2013) 0.94
Remission in ankylosing spondylitis treated with anti-TNF-α drugs: a national multicentre study. Rheumatology (Oxford) (2013) 0.94
Biological treatments: new weapons in the management of monogenic autoinflammatory disorders. Mediators Inflamm (2013) 0.93
Serpins, immunity and autoimmunity: old molecules, new functions. Clin Rev Allergy Immunol (2013) 0.93
Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmun Rev (2012) 0.92
Anakinra treatment in drug-resistant Behcet's disease: a case series. Clin Rheumatol (2013) 0.92
Rituximab in refractory idiopathic inflammatory myopathies and antisynthetase syndrome: personal experience and review of the literature. Immunol Res (2013) 0.92
Long-term efficacy and improvement of health-related quality of life in patients with Takayasu's arteritis treated with infliximab. Clin Exp Rheumatol (2012) 0.91
Co-stimulatory modulation in rheumatoid arthritis: the role of (CTLA4-Ig) abatacept. Autoimmun Rev (2008) 0.91
Prevalence of calcium pyrophosphate and monosodium urate crystals in synovial fluid of patients with previously diagnosed joint diseases. Joint Bone Spine (2012) 0.91
Monogenic autoinflammatory syndromes: state of the art on genetic, clinical, and therapeutic issues. Int J Rheumatol (2013) 0.91
Recommendations for the use of biologic therapy in the treatment of psoriatic arthritis: update from the Italian Society for Rheumatology. Clin Exp Rheumatol (2011) 0.90
High-density lipoproteins downregulate CCL2 production in human fibroblast-like synoviocytes stimulated by urate crystals. Arthritis Res Ther (2010) 0.90
Biomechanical assessment of balance and posture in subjects with ankylosing spondylitis. J Neuroeng Rehabil (2012) 0.90
Effects of an educational-behavioral joint protection program on people with moderate to severe rheumatoid arthritis: a randomized controlled trial. Clin Rheumatol (2007) 0.90
Gout impacts on function and health-related quality of life beyond associated risk factors and medical conditions: results from the KING observational study of the Italian Society for Rheumatology (SIR). Arthritis Res Ther (2013) 0.90
Serologic profile and mortality rates of scleroderma renal crisis in Italy. J Rheumatol (2009) 0.90
Joint and bone assessment in hand osteoarthritis. Clin Rheumatol (2013) 0.89
Distribution of HLA-B27 subtypes in Sardinia and continental Italy and their association with spondylarthropathies. Arthritis Rheum (2005) 0.89
Emerging and critical issues in the pathogenesis of lupus. Autoimmun Rev (2012) 0.89
Miscellaneous non-inflammatory musculoskeletal conditions. Blau syndrome. Best Pract Res Clin Rheumatol (2011) 0.89
Cytokine levels in human synovial fluid during the different stages of acute gout: role of transforming growth factor β1 in the resolution phase. Ann Rheum Dis (2012) 0.89
A combination therapy protocol of plasmapheresis, intravenous immunoglobulins and betamethasone to treat anti-Ro/La-related congenital atrioventricular block. A case series and review of the literature. Autoimmun Rev (2013) 0.88
YKL-40 as a marker of joint involvement in inflammatory bowel disease. Clin Chem (2003) 0.88
A new CARD15 mutation in Blau syndrome. Eur J Hum Genet (2005) 0.88
Clinical and radiographic distribution of structural damage in erosive and nonerosive hand osteoarthritis. Arthritis Care Res (Hoboken) (2012) 0.87
Elderly onset of primary Sjögren's syndrome: clinical manifestations, serological features and oral/ocular diagnostic tests. Comparison with adult and young onset of the disease in a cohort of 336 Italian patients. Joint Bone Spine (2011) 0.87
Intra-articular clodronate for the treatment of knee osteoarthritis: dose ranging study vs hyaluronic acid. Rheumatology (Oxford) (2009) 0.87
Blockade of intra-articular TNF in peripheral spondyloarthritis: its relevance to clinical scores, quantitative imaging and synovial fluid and synovial tissue biomarkers. Joint Bone Spine (2012) 0.87
Predictors of maternal and fetal complications in SLE patients: a prospective study. Immunol Res (2014) 0.86
Serum and salivary neopterin and interferon-gamma in primary Sjögren's syndrome. Correlation with clinical, laboratory and histopathologic features. Scand J Rheumatol (2003) 0.86
Effects of mud-bath treatment on fibromyalgia patients: a randomized clinical trial. Rheumatol Int (2007) 0.86
Synovial effusion and synovial fluid biomarkers in psoriatic arthritis to assess intraarticular tumor necrosis factor-α blockade in the knee joint. Arthritis Res Ther (2010) 0.85
Epithelial CXCR3-B regulates chemokines bioavailability in normal, but not in Sjogren's syndrome, salivary glands. J Immunol (2006) 0.85
Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year study. Rheumatology (Oxford) (2010) 0.85
Methods used to assess remission and low disease activity in rheumatoid arthritis. Autoimmun Rev (2009) 0.84
Pregnancy and vasculitis: a systematic review of the literature. Autoimmun Rev (2011) 0.84
JAK/STAT/PKCδ molecular pathways in synovial fluid T lymphocytes reflect the in vivo T helper-17 expansion in psoriatic arthritis. Immunol Res (2014) 0.83
Serological markers of erosive hand osteoarthritis. Eur J Intern Med (2012) 0.83
"Are there any evidences for using the intra-articular TNF-α blockade in resistant arthritis?". Joint Bone Spine (2011) 0.83
Polymer-supported organic catalysts. Chem Rev (2003) 0.82
Anti-SSA/Ro-related congenital heart block in two family members of different generations: Comment on the article by Clancy et al. Arthritis Rheum (2005) 0.82
Serological markers in psoriatic arthritis: promising tools. Exp Biol Med (Maywood) (2013) 0.82
Anti-SAE antibodies in autoimmune myositis: identification by unlabelled protein immunoprecipitation in an Italian patient cohort. J Immunol Methods (2012) 0.82
The impact of knee and hip chondrocalcinosis on disability in older people: the ProVA Study from northeastern Italy. Ann Rheum Dis (2011) 0.81
Effect of pregnancy on serum cytokines in SLE patients. Arthritis Res Ther (2012) 0.81
Plasma exchange and immunoadsorption effectively remove antiphospholipid antibodies in pregnant patients with antiphospholipid syndrome. J Clin Apher (2012) 0.81
Aging and osteoarthritis. Aging Clin Exp Res (2003) 0.80
The tumor necrosis factor-{alpha}-blocking agent infliximab inhibits interleukin 1beta (IL-1beta) and IL-6 gene expression in human osteoblastic cells. J Rheumatol (2009) 0.80
Prognosis of scleroderma renal crisis: a long-term observational study. Nephrol Dial Transplant (2012) 0.80
Increased apoptosis in circulating lymphocyte cultures of anti-RNA polymerase III positive patients with systemic sclerosis. Rheumatol Int (2008) 0.80
Antisynthetase syndrome with refractory polyarthritis and fever successfully treated with the IL-1 receptor antagonist, anakinra: A case report. Joint Bone Spine (2007) 0.80
The clinical performance of a chemiluminescent immunoassay in detecting anti-cardiolipin and anti-β2 glycoprotein I antibodies. A comparison with a homemade ELISA method. Clin Chem Lab Med (2015) 0.80